Ventyx Biosciences, Inc. $VTYX Shares Bought by Redmile Group LLC

Key Points

• Redmile Group LLC significantly increased its holdings in Ventyx Biosciences by 1,164.1% in the first quarter, now owning 1,569,793 shares worth $1,805,000.
• Wall Street analysts have upgraded Ventyx Biosciences from a "sell" to a "hold" rating, with the stock averaging a rating of "Moderate Buy" and a price target of $7.50.
• Ventyx Biosciences has reported a quarterly EPS of ($0.38), surpassing expectations, while the stock's market cap is currently $171.14 million.

Redmile Group LLC boosted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 1,164.1% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 1,569,793 shares of the company's stock after acquiring an additional 1,445,615 shares during the quarter. Redmile Group LLC owned about 2.21% of Ventyx Biosciences worth $1,805,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of VTYX. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Ventyx Biosciences in the first quarter worth about $28,000. Cerity Partners LLC purchased a new stake in shares of Ventyx Biosciences in the first quarter worth about $56,000. MetLife Investment Management LLC raised its holdings in Ventyx Biosciences by 76.0% in the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after purchasing an additional 11,543 shares during the period. CWM LLC boosted its position in Ventyx Biosciences by 1,733.8% during the first quarter. CWM LLC now owns 53,088 shares of the company's stock worth $61,000 after purchasing an additional 50,193 shares in the last quarter. Finally, Cutter & CO Brokerage Inc. purchased a new position in Ventyx Biosciences during the first quarter worth approximately $62,000. Institutional investors and hedge funds own 97.88% of the company's stock.

Ventyx Biosciences Stock Down 3.1%

Shares of Ventyx Biosciences stock traded down $0.08 during mid-day trading on Friday, reaching $2.52. 429,444 shares of the stock traded hands, compared to its average volume of 569,336. The business has a 50-day moving average of $2.65 and a 200 day moving average of $1.93. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $3.39. The stock has a market capitalization of $179.70 million, a PE ratio of -1.50 and a beta of 0.95.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.07. On average, equities research analysts expect that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Ventyx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $7.50.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.